[et_pb_section fb_built=”1″ custom_padding_last_edited=”off|desktop” _builder_version=”4.16″ background_color=”#26619A” custom_padding=”0px||0px||false|false” custom_padding_tablet=”24vh||2vh||false|false” background_color_gradient_direction_tablet=”360deg” background_color_gradient_stops_tablet=”#2b87da 49%|#29c4a9 79%” background_color_gradient_start_position_tablet=”49%” background_color_gradient_end_position_tablet=”79%” background_size_tablet=”cover” background_position_tablet=”center_right” background_position_phone=”center_right” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”2_5,3_5″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” max_width=”100%” custom_padding=”0px||0px|4%|false|false” custom_padding_tablet=”0px|||0%|false|false” custom_padding_phone=”” locked=”off” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”30px||||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_ds_breadcrumbs module_class=”light” _builder_version=”4.5.1″ _module_preset=”default” locked=”on” global_colors_info=”{}”][\/et_pb_ds_breadcrumbs][et_pb_text _builder_version=”4.16″ header_font=”|700|||||||” header_font_size=”42px” header_line_height=”1.15em” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”3em||20px||false|false” custom_margin_tablet=”3em||||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” header_font_size_tablet=”34px” header_font_size_phone=”24px” header_font_size_last_edited=”on|desktop” module_alignment_tablet=”” module_alignment_phone=”” module_alignment_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font_size=”24px” background_enable_image=”off” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”||40px||false|false” custom_padding=”||||false|false” text_font_size_tablet=”20px” text_font_size_phone=”16px” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
The ASPirin in Reducing Events in the Elderly (ASPREE) study continues to explore new ways to improve health and quality of life amongst older adults. The results will be relevant to many aging people around the world.<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/Image-4-New-LR.jpg” custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_code _builder_version=”4.16″ _module_preset=”default” height=”34em” height_tablet=”250px” height_phone=”250px” height_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” padding_right_2=”0px” padding_left_2=”0px” padding_top_bottom_link_2=”false” padding_left_right_link_2=”true” module_class=”texture-left” _builder_version=”4.16″ _module_preset=”default” inner_max_width=”80%” custom_margin=”||||false|false” custom_padding=”||90px||false|false” border_color_bottom=”#bdbec0″ global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Anchors” _builder_version=”4.16″ text_font=”||||||||” text_text_color=”#26619a” header_font=”|||on|||||” header_2_font=”|||on|||||” header_2_font_size=”32px” header_3_line_height=”2em” custom_padding=”|||0px||” text_font_size_tablet=”28px” text_font_size_phone=”24px” text_font_size_last_edited=”on|phone” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” locked=”off” global_colors_info=”{}”]<\/p>\n
<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”PUT CONTENT BELOW AS A TEXT AND IMAGES” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” custom_padding=”|0px||0px|true|true” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”COMPONENTS OF THE ASPREE PROJECT: Text” _builder_version=”4.20.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
ASPREE (ASPirin in Reducing Events in the Elderly) involved 19,114 community dwelling older adults:<\/p>\n
The principal results of ASPREE were published in the New England Journal of Medicine<\/em> in 2018. These provided the first high quality findings on the value of low-dose aspirin for primary prevention in healthy older adults, mostly aged 70 and over.<\/p>\n Media announcement of the trial’s results can be viewed here<\/a>.<\/p>\n A series of additional reports have been published describing the impact of low- dose aspirin on other conditions including depression, cognitive decline and sepsis. These can be accessed here.<\/a><\/p>\n Prominent\u00a0US guidelines<\/a> incorporated ASPREE findings, recommending against routine use of aspirin for primary prevention in healthy adults aged 70 and older.<\/p>\n \u201cFor a large fraction of our professional lives, we have been telling patients who suffered from a prior major cardiovascular event, such as myocardial infarction or stroke, that daily ingestion of about 82 mg of aspirin a day could help protect against further events. Since the intervention was perceived to have few side effects, many of us advised previously healthy older adults to take a daily low-dose aspirin to protect against cardiovascular disease. This daily regimen was inexpensive, low-risk \u2014 or so we thought \u2014 and appeared to provide a benefit. But a trio of studies published last September found that a daily aspirin doesn\u2019t do much good, and may even cause harm,\u201d wrote Jeffrey M. Drazen, MD, Editor-in-Chief of the\u00a0New England Journal of Medicine.<\/em>\u2019<\/a><\/p>\n<\/blockquote>\n Details of relevant clinical events are sourced from medical records. Participant health outcomes are adjudicated on evidence provided by medical records.<\/p>\n The ASPREE project is funded<\/a> by the National Institute on Aging<\/a>\u00a0and the\u00a0National Cancer Institute<\/a>\u00a0(NIA and NCI; both part of the US National Institutes of Health) the\u00a0National Health and Medical Research Council of Australia<\/a>, Victorian Cancer Agency<\/a> and Monash University<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ background_color=”#26619a” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/texture-2.png” background_size=”initial” background_position=”top_right” background_blend=”overlay” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Key features HEADER” _builder_version=”4.16″ _module_preset=”d100a70a-4a1b-4c0a-852d-deb7ebdb8d36″ header_font=”|600||on|||||” header_text_align=”left” header_2_font=”|600||on|||||” header_2_text_align=”left” header_2_font_size=”32px” text_orientation=”center” background_layout=”dark” custom_margin=”||0px||false|false” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” box_shadow_style=”preset1″ box_shadow_blur=”8px” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/USA1.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Text” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” box_shadow_style=”preset1″ box_shadow_blur=”8px” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/hal-gatewood-iPl3q-gEGzY-unsplashcrop.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Text” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n Published September 18, 2018<\/strong><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” box_shadow_style=”preset1″ box_shadow_blur=”8px” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/3\/2021\/07\/022_knee-MRI_359292copyrightMonash.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Text” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n ASPREE embedded a large number of additional sub-studies<\/a> exploring whether low-dose aspirin affected various aspects of health including: hearing loss, age-related macular degeneration, falls and fractures, cancer, sepsis, microbiome and more!<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” admin_label=”TABBED CONTENT (LIGHT)” module_id=”scroll_tab1″ module_class=”tabs” _builder_version=”4.16″ _module_preset=”default” inner_max_width=”80%” custom_margin=”||||false|false” custom_padding=”||90px||false|false” border_width_bottom=”1px” border_color_bottom=”#bdbec0″ global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ text_text_color=”#26619a” header_2_font=”||||||||” header_2_font_size=”32px” header_3_font=”|600|||||||” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n Select question below<\/p>\n <\/p>\n [\/et_pb_text][et_pb_text admin_label=”DO NOT DELETE” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0px||0px||false|false” locked=”on” global_colors_info=”{}”][\/et_pb_text][et_pb_text admin_label=”What does the ASPREE-XT study involve?” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n What does the ASPREE-XT study involve?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”Implications clinical practice” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n What are the implications of ASPREE results for clinical practice?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”cancer outcomes” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n Why is ASPREE and ASPREE-XT looking at cancer outcomes?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”what happens cog decline” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n What happens when a patient may have cognitive decline?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”collection medical records” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n How does ASPREE collect participant medical records?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”what happens – study endpoint? ” module_class=”tab-link” _builder_version=”4.19.3″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n What happens when patients reach a study endpoint?<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”FAQ TAB TITLE” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n What sub-studies were incorporated into the ASPREE project?<\/a><\/p>\n [\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” custom_margin=”1em||-1em||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][\/et_pb_divider][et_pb_text admin_label=”XT protocol” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n ASPREE-XT Study Protocol<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”Trial protocol” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||||false|false” custom_padding=”0.5em||0.5em||true|false” global_colors_info=”{}”]<\/p>\n ASPREE Clinical Trial Protocol<\/a><\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.16″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||0px||false|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider divider_weight=”6px” disabled_on=”off|off|on” _builder_version=”4.16″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”what project involves” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n A:<\/strong>\u00a0ASPREE-XT is conducted similarly\u00a0to the ASPREE clinical trial, but participants are no longer taking study tablets (100mg aspirin or a matched placebo).<\/p>\n Primary Care Providers (PCPs) and research staff reinforce the importance of the ASPREE study. We acknowledge their contributions and dedication to this significant research.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Implications for practice ” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Cancer outcomes” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n <\/p>\n A:\u00a0<\/strong>ASPREE reported<\/a> a slightly higher death rate amongst the aspirin-treated group than in those taking placebo.\u00a0 It was mostly explained by more rapid progress of cancers that were already advanced when they were diagnosed<\/a>.<\/p>\n This finding was based on small numbers and could have occurred by chance. Also, in many previous aspirin trials, no similar findings were observed and there was considerable evidence suggesting that aspirin may lead to a reduction in cancer.<\/p>\n However, studies that have described a reduction in cancer mortality (particularly colorectal cancer mortality) have found that the effect starts to appear only 5-10 years after a period of prolonged intake of aspirin. Mostly these findings have originated from studies in younger populations.<\/p>\n At present the existence of a cancer-reducing effect of aspirin is controversial, especially since the findings of ASPREE were published.<\/a> The continued follow-up of ASPREE participants after a median 4.7 years of intervention will determine whether the early increase in cancer mortality is followed by a later decline.<\/p>\n View selected cancer papers here<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Cog decline” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n A:\u00a0 <\/strong>At every annual study visit, our research staff track the cognitive state of study participants by administering the Modified Mini-Mental State (3MS); an internationally accepted neuro-cognitive screening tool that uses a 100-point scale. The 3MS is more sensitive to cognitive change than the MMSE, which uses a 30-point scale.<\/p>\n If a participant\u2019s 3MS score declines to a predetermined level (set by population normative data) at any point during the study then: Subsequently:<\/p>\n ASPREE does not initiate clinical assessment or treatment of cognitive decline. The literature highlights the value of early diagnosis of dementia, as there are now effective interventions that may improve patient quality of life. Recent research also shows a reversible cause may be present in some cases.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”medical records” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ custom_padding=”4px|||||” global_colors_info=”{}”]<\/p>\n All study participants have consented for trained ASPREE staff members to review their medical records and collect documentation of clinical events from their Primary Care Provider (PCP), specialist and hospital.<\/p>\n Medical records provide the documentation necessary for ASPREE investigators with the relevant clinical expertise, to adjudicate whether a participant has reached a predetermined study \u2018endpoint\u2019, such as cancer or dementia. This process is critical to the project\u2019s findings and maintenance of high-quality data.<\/p>\n Our research staff use key terms to search medical records for evidence of clinical health events\u00a0studied in the ASPREE project. For instance, key search terms used to identify stroke events include ‘stroke,’ ‘CVA’, ‘cerebrovascular accident,’ and ‘cerebral infarct.’\u00a0\u00a0<\/p>\n PCPs are always welcome to proactively advise ASPREE of their patient\u2019s clinical event, however, we understand that most practices are too busy. Our trained staff securely and confidentially collect this information when they review the participant\u2019s medical record.\u00a0<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”study endpoint” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n A: <\/strong>We ask all participants to continue in the follow-up ASPREE-XT Study, attending scheduled study visits where ever possible. Tracking the ongoing health of each participant after a study endpoint is pivotal.<\/p>\n All health data from ASPREE participants collected for the duration of the project greatly contribute to the study\u2019s quality and findings. [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”FAQ TAB CONTENT” module_id=”scroll_tab2″ module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”sub-studies” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n A: <\/strong>Large-scale research projects take many years and costs tens of millions of dollars.\u00a0Because of the cost and the logistics, such studies are infrequently undertaken. ASPREE was a rare opportunity to undertake many ancillary studies to provide important public health information. Study participants largely found sub-studies interesting and engaging. View ASPREE sub-studies here<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”DIVIDER FROM FAQ” _builder_version=”4.16″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider show_divider=”off” admin_label=”DO NOT DELETE” _builder_version=”4.16″ _module_preset=”default” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”XT protocol” _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n ASPREE-XT is a longitudinal, observational follow-up study of ASPREE participants to determine whether there are long-lasting (legacy) effects of a median 4.7 years of treatment with daily low-dose aspirin on the key outcome measures of:<\/p>\n 1) Cancer, metastases and cancer mortality Download the ASPREE-XT Study Protocol<\/a><\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Trial protocol” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#000000″ global_colors_info=”{}”]<\/p>\n <\/p>\n\n
\n
\u00a0<\/h3>\n
ASPREE-XT (eXTension) FOLLOW-UP STUDY (2017 – 2024)<\/h3>\n
\n
\u00a0<\/h3>\n
Funding<\/h3>\n
Key features <\/h2>\n
ASPREE Features<\/strong><\/h3>\n
\n
ASPREE publications in NEJM<\/strong><\/h3>\n
\n
ASPREE Sub-studies<\/strong><\/h3>\n
Further information for clinicians<\/strong><\/h3>\n
Frequently asked questions<\/h2>\n
Q: What does the ASPREE\/ASPREE-XT study involve?<\/strong><\/h3>\n
\u00a0<\/h4>\n
Your role in ASPREE-XT<\/h4>\n
\n
\u00a0<\/h4>\n
Your patient\u2019s role in ASPREE-XT<\/h4>\n
\n
Frequently asked questions<\/h2>\n
Q: What are the implications of ASPREE findings for clinical practice?<\/strong><\/h3>\n
\n
Frequently asked questions<\/h2>\n
Q: Why are ASPREE and ASPREE-XT looking at cancer outcomes?<\/strong><\/h3>\n
Meta-analyses published in The Lancet by other researchers such as Rothwell et al. provided evidence in support of low-dose aspirin preventing cancers of the colon, oesophagus, lung and stomach.<\/em><\/h5>\n
Frequently asked questions<\/h2>\n
Q:\u00a0<\/strong>What happens when your patient may have cognitive decline?<\/strong><\/h3>\n
<\/strong><\/p>\n\n
\n
Frequently asked questions<\/h2>\n
Q:\u00a0<\/strong>How does ASPREE collect participant medical records?<\/strong><\/h3>\n
Frequently asked questions<\/h2>\n
Q: What happens when patients reach a study endpoint?<\/strong><\/h3>\n
<\/strong><\/p>\nFrequently asked questions<\/h2>\n
Q: What sub-studies were incorporated into the ASPREE project?<\/strong><\/h3>\n
ASPREE-XT Study Protocol<\/h2>\n
Summary<\/h3>\n
2) The composite primary ASPREE-XT outcome of dementia, disability or death
3) Secondary ASPREE-XT outcomes of all-cause mortality, dementia, physical disability, cancer, mild cognitive impairment, depression and frailty, incidence of cardiovascular disease including fatal and non-fatal stroke, major hemorrhage.<\/p>\n\n
ASPREE Clinical Trial Protocol<\/h2>\n
Summary<\/h3>\n
\n